Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 1/2013

01-02-2013

Increased Risk of Second Lung Cancer in Hodgkin’s Lymphoma Survivors: A Meta-analysis

Authors: Ezzeldin M. Ibrahim, Ghieth A. Kazkaz, Khaled M. Abouelkhair, Mubarak M. Al-Mansour, Turki M. Al-Fayea, Meteb Al-Foheidi, Ali M. Bayer, Osama A. Elmasri

Published in: Lung | Issue 1/2013

Login to get access

Abstract

Background

Patients treated for Hodgkin’s lymphoma (HL) have a higher risk of developing second lung cancer (SLC) compared with the general population. The aim of this meta-analysis was to quantify such risk and to analyze contributing risk factors in HL survivors.

Methods

According to predefined selection criteria, a literature search identified 21 studies that were included in the analysis.

Results

After eliminating overlapping or duplicate data, 793 (76 % males) incidences of SLC were encountered in 74,831 patients (58 % males) with HL over a median follow-up of 11.5 years. The median age at HL diagnosis and the median age at SLC diagnosis were 33.0 and 45.9, respectively. The mean latency between treatment of HL and development of SLC was 11.5 years. The pooled relative risk (RR) of SLC was 4.62 (95 % confidence interval [CI], 3.18–6.70], I 2 = 98 %), with a median absolute excess rate of 10.4 per 10,000 person-years. RR was positively related to study size, male-to-female ratio, institutional versus population-based data sets, and the use of any radiotherapy (RT) or combined modality therapy (CMT), while age at diagnosis of HL was not significant. The highest risk was shown among patients aged 15–24 years (RR = 8.76 [95 % CI, 4.55–16.89]), while the lowest risk occurred in patients ≥55 years at primary treatment (RR = 2.88 [95 % CI, 2.33–3.56]). RR increased by increasing duration of follow-up, reaching the highest value at 10–14 years (RR = 4.17 [95 % CI, 3.62–8.81]), but did not increase after ≥15 years (RR = 4.01 [95 % CI, 2.68–5.98]). RT only, CMT, or chemotherapy only was associated with RR (95 % CI) of 4.88 (3.14–7.60), 5.15 (4.08–6.50), and 2.39 (1.60–3.55), respectively. Patients with SLC demonstrated poor prognosis.

Conclusions

The current meta-analysis provided a detailed estimate of the risk of SLC among HL survivors. The obtained results may provide guidelines concerning lung cancer screening for this population.
Literature
1.
Herbst C, Rehan FA, Skoetz N, Bohlius J, Brillant C, Schulz H, Monsef I, Specht L, Engert A (2011) Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev (2):CD007110. doi:10.​1002/​14651858.​CD007110.​pub2
2.
3.
4.
Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD Jr, Chauvenet AR (1997) Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 15(8):2769–2779PubMed
5.
Canellos GP (1975) Letter: second malignancies complicating Hodgkin’s disease in remission. Lancet 1(7919):1294PubMedCrossRef
6.
7.
Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Ferme C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J (2006) Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 17(12):1749–1760. doi:10.​1093/​annonc/​mdl302 PubMedCrossRef
8.
Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC (2010) Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 152(7):444–455; W144–454. doi:10.​1059/​0003-4819-152-7-201004060-00009
9.
Ibrahim EM, Abouelkhair KM, Kazkaz GA, Al-Masri OA, Al-Foheidi M (2012) Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis. BMC Cancer 12:197PubMedCrossRef
10.
Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P (2011) Strengthening the reporting of observational studies in epidemiology–molecular epidemiology (STROBE–ME): an extension of the STROBE statement. PLoS Med 8(10):e1001117. doi:10.​1371/​journal.​pmed.​1001117 PubMedCrossRef
11.
Clayton D, Hills M (1993) Statistical models in epidemiology. Oxford University Press, Oxford
12.
Alder N, Fenty J, Warren F, Sutton AJ, Rushton L, Jones DR, Abrams KR (2006) Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry. Am J Epidemiol 164(5):405–420. doi:10.​1093/​aje/​kwj252 PubMedCrossRef
13.
14.
15.
16.
17.
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCrossRef
18.
List AF, Doll DC, Greco FA (1985) Lung cancer in Hodgkin’s disease: association with previous radiotherapy. J Clin Oncol 3(2):215–221PubMed
19.
Coleman MP, Bell CM, Fraser P (1987) Second primary malignancy after Hodgkin’s disease, ovarian cancer and cancer of the testis: a population-based cohort study. Br J Cancer 56(3):349–355PubMedCrossRef
20.
21.
Henry-Amar M (1992) Second cancer after the treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s Disease. Ann Oncol 3(Suppl 4):117–128PubMedCrossRef
22.
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R (1994) Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 12(2):312–325PubMed
23.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, Farber LR, Kiehl RK, Cardinale J, Cooper DL (1996) Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14(9):2435–2443PubMed
24.
Hoppe RT (1997) Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol 8(Suppl 1):115–118PubMedCrossRef
25.
Munker R, Grutzner S, Hiller E, Aydemir U, Enne W, Dietzfelbinger H, Busch M, Haas R, Emmerich B, Schmidt M, Duhmke E, Holzel D, Wilmanns W (1999) Second malignancies after Hodgkin’s disease: the Munich experience. Ann Hematol 78(12):544–554PubMedCrossRef
26.
Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, van’t Veer MB, Curtis RE, Holowaty EJ, Andersson M, Wiklund T, Gospodarowicz M, Travis LB (2000) Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 18(12):2435–2443PubMed
27.
Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18(3):498–509PubMed
28.
van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM (2000) Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 18(3):487–497PubMed
29.
Cellai E, Magrini SM, Masala G, Alterini R, Costantini AS, Rigacci L, Olmastroni L, Papi MG, Spediacci MA, Innocenti F, Bellesi G, Ferrini PR, Biti G (2001) The risk of second malignant tumors and its consequences for the overall survival of Hodgkin’s disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 49(5):1327–1337PubMedCrossRef
30.
31.
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van’t Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 20(16):3484–3494. doi:10.​1200/​jco.​2002.​09.​038 PubMedCrossRef
32.
Foss AA, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002) Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age and follow-up time. Ann Oncol 13(11):1786–1791. doi:10.​1093/​annonc/​mdf289 CrossRef
33.
Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100(6):1989–1996. doi:10.​1182/​blood-2002-02-0634 PubMedCrossRef
34.
Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol 21(23):4386–4394. doi:10.​1200/​jco.​2003.​11.​059 PubMedCrossRef
35.
Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, Engert A (2004) Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15(7):1079–1085. doi:10.​1093/​annonc/​mdh273 PubMedCrossRef
36.
Petrakova K, Koukalova H, Soumarova R, Palacova M, Blazkova S, Vyzula R (2004) Relative risk (RR) of second malignancies (SM) in patients treated by “risk” radiotherapy (RT) or “risk” RT plus chemotherapy (CT) in comparison with patients treated by CT {±} “non risk RT” for Hodgkin’s disease (HD). In: ASCO meeting abstracts, vol 22(14_suppl), p 6695
37.
Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 117(6):1806–1816. doi:10.​1182/​blood-2010-04-278796 PubMedCrossRef
38.
Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Rohatiner AZ, Linch DC (2011) Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol 29(31):4096–4104. doi:10.​1200/​jco.​2011.​34.​8268 PubMedCrossRef
39.
40.
41.
Weiss W (1997) Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest 111(5):1414–1416PubMedCrossRef
42.
Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, Lister TA, Rohatiner AZ, Vaughan Hudson G, Williams MV, Linch DC (2001) Lung cancer after Hodgkin’s disease: a nested case-control study of the relation to treatment. J Clin Oncol 19(6):1610–1618PubMed
43.
Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94(3):182–192PubMedCrossRef
44.
45.
Davis FG, Boice JD Jr, Kelsey JL, Monson RR (1987) Cancer mortality after multiple fluoroscopic examinations of the chest. J Natl Cancer Inst 78(4):645–652PubMed
46.
van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R (1995) Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87(20):1530–1537PubMedCrossRef
47.
Kaldor JM, Day NE, Bell J, Clarke EA, Langmark F, Karjalainen S, Band P, Pedersen D, Choi W, Blair V et al (1992) Lung cancer following Hodgkin’s disease: a case-control study. Int J Cancer 52(5):677–681PubMedCrossRef
48.
Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA (1992) Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 304(6835):1137–1143PubMedCrossRef
49.
Swerdlow AJ, Barber JA, Horwich A, Cunningham D, Milan S, Omar RZ (1997) Second malignancy in patients with Hodgkin’s disease treated at the Royal Marsden Hospital. Br J Cancer 75(1):116–123PubMedCrossRef
50.
51.
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544. doi:10.​1200/​jco.​2005.​04.​4859 PubMedCrossRef
52.
Kadan-Lottick NS, Robison LL, Gurney JG, Neglia JP, Yasui Y, Hayashi R, Hudson M, Greenberg M, Mertens AC (2002) Childhood cancer survivors’ knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA 287(14):1832–1839. doi:joc11569 [pii]PubMedCrossRef
53.
Emmons K, Li FP, Whitton J, Mertens AC, Hutchinson R, Diller L, Robison LL (2002) Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 20(6):1608–1616PubMedCrossRef
54.
55.
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409. doi:10.​1056/​NEJMoa1102873 PubMedCrossRef
56.
57.
Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van’t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19):1916–1927. doi:10.​1056/​NEJMoa064601 PubMedCrossRef
58.
Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652. doi:10.​1056/​NEJMoa1000067 PubMedCrossRef
59.
Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T (2011) Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80(1):199–205. doi:10.​1016/​j.​ijrobp.​2010.​09.​007 PubMedCrossRef
Metadata
Title
Increased Risk of Second Lung Cancer in Hodgkin’s Lymphoma Survivors: A Meta-analysis
Authors
Ezzeldin M. Ibrahim
Ghieth A. Kazkaz
Khaled M. Abouelkhair
Mubarak M. Al-Mansour
Turki M. Al-Fayea
Meteb Al-Foheidi
Ali M. Bayer
Osama A. Elmasri
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Lung / Issue 1/2013
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-012-9418-4

Other articles of this Issue 1/2013

Lung 1/2013 Go to the issue

OriginalPaper

Clinical Predictors of Mortality and Cause of Death in Lymphangioleiomyomatosis: A Population-based Registry

OriginalPaper

Comparison of Recruitment Manoeuvres in Ventilated Sheep with Acute Respiratory Distress Syndrome

OriginalPaper

Linear Probe Endobronchial Ultrasound Bronchoscopy with Guided Transbronchial Needle Aspiration (EBUS–TBNA) in the Evaluation of Mediastinal and Hilar Pathology: Introducing the Procedure to a Teaching Institution

OriginalPaper

A Method for Determining Optimal Mean Airway Pressure in High-Frequency Oscillatory Ventilation

ReviewPaper

Meta-Analysis: The Association Between HIV Infection and Extrapulmonary Tuberculosis

ReviewPaper

Diagnostic Workup for Diffuse Parenchymal Lung Disease: Schematic Flowchart, Literature Review, and Pitfalls
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits